Browse
Submit Data
Databases
API
Help

Dataset Information

21 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy.

ABSTRACT: Interventions: Tri-weekly XELIRI+ bevacizumab Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2621504 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Phase I /II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.

Project description:Interventions: XELIRI+ bevacizumab Capecitabine:2000mg/m2/day d1-8 Irinotecan:180mg/m2 d1 Bevacizumab:5mg/kg d1 Q2w Primary outcome(s): Phase I part To determine Safety in 1st cycle by Bi-weekly XELIRI+bevacizumab. Phase II part Progression Free Survival Study Design: Single arm Non-randomized

| 2619445 | ecrin-mdr-crc

A Phase I /II Study of Tri-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.

Project description:Interventions: XELIRI+ bevacizumab Primary outcome(s): Phase I part Estimated the dose limiting toxicities in 1st cycle. Phase II part Progressiom Free Survival Study Design: Single arm Non-randomized

| 2618941 | ecrin-mdr-crc

A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

Project description:The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.

| 2334327 | ecrin-mdr-crc

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with ovarian cancer

Project description:Abstract This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the effectiveness and safety of weekly paclitaxel with that of three‐weekly paclitaxel, in combination with carboplatin, as first‐line chemotherapy treatment for ovarian cancer.

| S-EPMC6457624 | biostudies-literature

A tri-species Aspergillus array

Project description:This SuperSeries is composed of the following subset Series: GSE9275: A tri-species Aspergillus array (nidulans arrays) GSE9276: A tri-species Aspergillus array (niger arrays) GSE9277: A tri-species Aspergillus array (oryzae arrays) Keywords: SuperSeries Refer to individual Series

2008-02-10 | E-GEOD-9298 | biostudies-arrayexpress

A Phase II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy

Project description:Interventions: XELIRI plus bevacizumab therapy Capecitabine: 2000 mg/m2 day1 to 8 CPT11 150mg/m2 day1 Bevacizumab: 10mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity. Primary outcome(s): progression free survival and safety Study Design: Single arm Non-randomized

| 2624679 | ecrin-mdr-crc

Anguilla japonica isolate:Three weekly SPH injections

Project description:Anguilla japonica isolate:Three weekly SPH injections Transcriptome or Gene expression

| PRJNA339349 | ENA

Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than Auranofin

Project description:Anticancer drugs that target cellular antioxidant systems have recently attracted much attention. Auranofin (AF) is currently evaluated in several clinical trials as an anticancer agent and targets the cytosolic and mitochondrial forms of the selenoprotein thioredoxin reductase, Txnrd1 and Txnrd2. Recently, two novel Txnrd1 inhibitors (TRi-1 and TRi-2) have been developed that showed anticancer efficacy comparable to AF, but with lower mitochondrial toxicity. However, the cellular action mechanisms of these drugs have not yet been thoroughly studied. Here we used several proteomics analyses to determine the effects of AF, TRi-1 and TRi-2 when used at IC50 concentrations with the mouse B16 melanoma and LLC lung adenocarcinoma cells, as these are often used for preclinical mouse models in evaluation of anticancer drugs. The results demonstrate that TRi-1 and TRi-2 are more specific Txnrd1 inhibitors than AF and reveal additional AF-specific effects on the cellular proteome. Interestingly, AF triggered stronger Nrf2-driven antioxidant responses than the other two compounds. Furthermore, AF affected several additional proteins, including Gsk3a, Gsk3b, Mcmbp and Eefsec, implicating additional effects on glycogen metabolism, cellular differentiation, inflammatory pathways, DNA replication and selenoprotein synthesis processes. Our proteomics data should represent a resource for researchers interested in the multidimensional analysis of proteome changes associated with oxidative stress in general, and the effects of Txnrd inhibitors and AF protein targets in particular.

2021-12-15 | PXD028398 | Pride

Tri-4C: efficient and quantitative analysis of enhancer loops at hundred base pair resolution (Tri-4C)

Project description:Enhancer looping governs gene regulatory circuitry but is challenging to detect. Here we present Tri-4C, an ultrafine mapping method for distal chromatin contacts using triple restriction enzyme (RE) digestion. Tri-4C identifies enhancer loops that are undetectable by current single RE- based methods and reveals quantitative loop strengths in enhancer interaction networks underlying dynamic gene control. This multi-RE approach may be applied to general 3C-derived methods for accurate detection of enhancer loops.

2020-08-28 | GSE119187 | GEO

Forensic Tri-allelic SNP sequencing

Project description:Forensic tri-allelic SNP genotyping using nanopore sequencing

| PRJEB25630 | ENA